US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Silexion Therapeutics Corp

1.11

-0.1400-11.20%

Post-market: 1.120.0100+0.90%17:19 EDT

Volume:580.96K

Turnover:683.77K

Market Cap:9.34M

PE:-0.91

High:1.26

Open:1.23

Low:1.11

Close:1.25

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Silexion Therapeutics 2024 Net Income $(16.5)M Vs $(5.1)M In 2023

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLXN"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.11,"timestamp":1742414400000,"preClose":1.25,"halted":0,"volume":580961,"hourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.11,"latestTime":"17:19 EDT","volume":20530,"amount":22995.700219000002,"timestamp":1742419178605},"delay":0,"changeRate":-0.112,"change":-0.14,"floatShares":5231700,"shares":8414615,"eps":-1.215216,"lyrEps":0.386244,"amount":683771.5186143,"amplitude":0.11848,"volumeRatio":0.2732,"dividePrice":0,"prevYearClose":2.01,"fiveDayClose":1.38,"twentyDayClose":0.9877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5231700,"roa":"--","roe":"--","lyrEps":0.386244,"volumeRatio":0.2732,"shares":8414615,"dividePrice":0,"high":1.2581,"amplitude":0.11848,"preClose":1.25,"low":1.11,"week52Low":0.575,"pbRate":"--","week52High":122.0184,"institutionHeld":0,"latestPrice":1.11,"committee":-0.974612,"eps":-1.215216,"divideRate":0,"volume":580961,"delay":0,"ttmEps":-1.215216,"open":1.23,"prevYearClose":2.01,"prevWeekClose":1.31,"prevMonthClose":1.07,"prevQuarterClose":2.01,"fiveDayClose":1.38,"twentyDayClose":0.9877,"sixtyDayClose":2.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730520000000},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SLXN\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520326879","title":"Silexion Therapeutics 2024 Net Income $(16.5)M Vs  $(5.1)M In 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2520326879","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520326879?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:32","pubTimestamp":1742329938,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics 2024 Net Income $(16.5)M Vs  $(5.1)M In 2023","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44385979/silexion-therapeutics-2024-net-income-16-5-m-vs-5-1-m-in-2023","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN","LENZ"],"gpt_icon":0},{"id":"2520834932","title":"Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520834932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520834932?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:29","pubTimestamp":1742329776,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nTUAC72RGR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2520693218","title":"Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520693218","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520693218?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:29","pubTimestamp":1742329740,"startTime":"0","endTime":"0","summary":"Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse mod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/18/3044999/0/en/Silexion-Therapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139","ORR","LENZ"],"gpt_icon":0},{"id":"2520652560","title":"PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2520652560","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520652560?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:15","pubTimestamp":1742213700,"startTime":"0","endTime":"0","summary":"Silexion's Groundbreaking Orthotopic Model Data and the Potential Expansion of its Development Plan Position SIL204 as Potential Transformative Therapy; Wall Street Maintains Buy Rating and $9 Price Target representing a signifcant premium of almost +600% over current prices; Silexion's new expanded development plan expected to be completed shortly; Precision Oncology M&A Market has heated up in recent years with a series of Multi-Billion Dollar Acquisitions in the field. NEW YORK, March 17, 2025----PESG Research releases a report covering Silexion Therapeutics’ * latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology's most challenging targets.Maxim Group has maintained its analysis of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-report-silexion-therapeutics-breakthrough-121500022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SLXN","LENZ","SLXNW"],"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":69}]}}